lanthionine ketimine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
lanthionine ketimine : A member of the class of 1,4-thiazines that is 3,6-dihydro-2H-1,4-thiazine substituted by carboxy groups at positions 3 and 5. It is a natural but non-proteogenic amino acid found in human urine and brain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 134340 |
| CHEBI ID | 89479 |
| SCHEMBL ID | 13438654 |
| MeSH ID | M0108739 |
| Synonym |
|---|
| yf5l3mw7rm , |
| unii-yf5l3mw7rm |
| lanthionine ketimine |
| 2h-1,4-thiazine-3,5-dicarboxylic acid, 3,6-dihydro- |
| 83711-67-5 |
| 3,6-dihydro-2h-1,4-thiazine-3,5-dicarboxylic acid |
| SCHEMBL13438654 |
| CHEBI:89479 |
| Q6487610 |
| DTXSID801003724 |
Lanthionine ketimine (LK) is a natural sulfur amino acid metabolite with potent neurotrophic activity. It binds to collapsin response mediator protein-2 (CRMP2), an abundant brain protein that interacts with multiple partners to regulate microtubule dynamics, neurite growth and retraction.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Lanthionine ketimine (LK) is a natural sulfur amino acid metabolite with potent neurotrophic activity. " | ( Lanthionine ketimine ethyl ester partially rescues neurodevelopmental defects in unc-33 (DPYSL2/CRMP2) mutants. Baxter, T; Benda, E; Hardin, T; Hensley, K; Holgado, AM; Hubbard, C; O'Brien, S; St John, E, 2013) | 3.28 |
| "Lanthionine ketimine (LK) is a natural sulfur amino acid metabolite which binds to collapsin response mediator protein-2 (CRMP2), an abundant brain protein that interacts with multiple partners to regulate microtubule dynamics, neurite growth and retraction, axonal transport, and neurotransmitter release. " | ( Lanthionine ketimine ester provides benefit in a mouse model of multiple sclerosis. Dupree, JL; Feinstein, DL; Hensley, K; Pelligrino, D; Polak, PE, 2015) | 3.3 |
| "Lanthionine ketimine (LK) is a natural brain sulfur amino acid metabolite with demonstrated anti-neuroinflammatory and neurotrophic activities." | ( Lanthionine ketimine ester promotes locomotor recovery after spinal cord injury by reducing neuroinflammation and promoting axon growth. Hensley, K; Kotaka, K; Nagai, J; Ohshima, T, 2017) | 2.62 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Lanthionine ketimine ester treatment substantially diminished cognitive decline and brain amyloid-β (Aβ) peptide deposition and phospho-Tau accumulation in 3 × Tg-AD mice and also reduced the density of Iba1-positive microglia." | ( A derivative of the brain metabolite lanthionine ketimine improves cognition and diminishes pathology in the 3 × Tg-AD mouse model of Alzheimer disease. Eslami, P; Gabbita, SP; Harris-White, ME; Hensley, K; Hristov, A; Johnson, MF; Venkova, K, 2013) | 1.38 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " An ultrahigh-pressure liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS) assay was developed to evaluate bioavailability by measuring these compounds in mouse serum, whole blood and brain tissue." | ( Analysis of lanthionine ketimine ethyl ester in mouse serum, whole blood and tissues using ultrahigh-pressure liquid chromatography/tandem mass spectrometry. Feinstein, DL; Hensley, K; Kowal, KE; Muchiri, RN; van Breemen, RB, 2018) | 0.86 |
| " This method is suitable for bioavailability and pharmacokinetic studies." | ( Analysis of lanthionine ketimine ethyl ester in mouse serum, whole blood and tissues using ultrahigh-pressure liquid chromatography/tandem mass spectrometry. Feinstein, DL; Hensley, K; Kowal, KE; Muchiri, RN; van Breemen, RB, 2018) | 0.86 |
| Role | Description |
|---|---|
| human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
| anti-inflammatory agent | Any compound that has anti-inflammatory effects. |
| neuroprotective agent | Any compound that can be used for the treatment of neurodegenerative disorders. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 1,4-thiazine | |
| dicarboxylic acid | Any carboxylic acid containing two carboxy groups. |
| sulfur-containing amino acid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (22.22) | 18.7374 |
| 1990's | 5 (18.52) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (48.15) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.90) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (3.45%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 28 (96.55%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||